Cynata Therapeutics (ASX:CYP) has reached a pivotal moment in its clinical development journey, marking the completion of the 100-day primary evaluation period for all participants in its Phase 2 trial of CYP-001, a stem cell therapy targeting acute graft-versus-host disease.
The milestone represents the final patient’s last visit in a rigorously designed study that enrolled 65 participants across Australia, the United States and Europe. Each patient received either a combination of steroids and CYP-001 or steroids and a placebo in a randomised, double blind, controlled setting. With the evaluation period now complete, the company has shifted its focus to compiling and analysing the data, with initial results expected in June 2026.
Cynata Chief Executive Officer Dr Kilian Kelly described the milestone as a major step forward, underscoring the urgent need for better treatments for a condition that remains both severe and difficult to manage. Acute graft versus host disease occurs when donor immune cells attack a transplant recipient’s body, affecting up to half of patients undergoing such procedures. Standard steroid treatments fail in roughly half of cases, leaving patients with limited options and historically poor survival outcomes.
CYP-001, developed using Cynata’s proprietary Cymerus platform, is designed to regulate immune responses and improve both recovery rates and long-term survival. Earlier Phase 1 results were encouraging, with a high proportion of patients responding to treatment and no major safety concerns reported. These findings helped position the therapy as a potentially meaningful advancement in a field where progress has been limited.
Beyond this trial, Cynata continues to advance a broader clinical pipeline. A Phase 3 study investigating CYP-004 for knee osteoarthritis remains on track, while an early-stage kidney transplantation trial is progressing following a positive safety review. Together, these programs reflect a strategy built around scalable stem cell technologies to address multiple serious conditions.